And hes a very obese, older, in his 80s, diabetic
The mechanisms and applications of GLP-1RAs in SLE remain largely unexplored, and their efficacy and safety need to be validated by further studies
Previously, GLP-1 medications which mimic the naturally occurring hormone glucagon-like peptide-1, which regulates blood sugar, digestion, and hunger had been approved only to treat obesity in the form of weekly, home-administered injections
They are generally manageable and typically improve over time
Employers have a real opportunity to step in, offer these treatments affordably and with dignity, and position themselves as employers of choice. While weighing the choice to cover GLP-1s, employer cost is a significant consideration, Midlam noted
Finally, most of the trials were not long enough to comply with the FDA recommendations regarding cardiovascular outcomes [24]